Aspirin after early stomach precancer or early cancer removal
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether taking aspirin after endoscopic removal of an early stomach condition can lower the chance of the cancer coming back or progressing. You may be considered if your early stomach findings were fully removed and you’re able to avoid certain medications that raise bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 19–70 and had an endoscopy to remove a high-grade stomach adenoma or early stomach cancer.
- Your pathology report after removal fits specific Japanese guideline criteria for “absolute” or “expanded” eligible cases.
- You either had a negative H. pylori test or you finished treatment to get rid of H. pylori (stomach bacteria).
- You have not been taking aspirin regularly (more than 3 times per week) in the 2 months before screening.
- You cannot use aspirin if you have reasons to avoid it, such as aspirin allergy or a bleeding-risk condition (for example, bleeding disorders, certain abnormal blood vessels, or active ulcers).
- You cannot be taking blood thinners or other antiplatelet medicines for medical treatment, and you’ve never had stomach surgery to remove part or all of it (gastrectomy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether testing for an infection called H. pylori and using simple blood/screening tests (pepsinogen testing) can help prevent stomach cancer and reduce stomach-cancer-related deaths. You would be followed for health outcomes to see if the approach works better than standard care.
This study looks at people with certain stomach symptoms or precancer risk factors when they get a camera test of the upper digestive tract (endoscopy). The goal is to learn how to better detect and evaluate stomach precancer conditions early, which may help guide treatment or follow-up.
This Phase 2 trial studies how aspirin affects specific “biomarkers” (measurable body signals) in people newly diagnosed with colon or rectal cancer. The goal is to see whether aspirin-related changes can help design more personalized prevention treatment plans.
This trial tests whether taking low-dose aspirin around the time of pancreatic head surgery (a Whipple-type operation) can improve outcomes by affecting platelet-driven clotting. You may be eligible if you have a tumor that can be surgically removed and your doctors plan a specific type of pancreatic operation.
This early-phase study tests whether adding aspirin to standard neoadjuvant chemotherapy can change immune (anti-tumor) features inside ovarian, fallopian tube, or peritoneal tumors. It may help doctors better understand which patients respond and how aspirin could make treatment work better.
This trial tests if ursodeoxycholic acid can reverse intestinal metaplasia (a precancerous stomach condition) in patients who have no H. pylori infection. The goal is to see if this medication can help lower the risk of stomach cancer.
Hear when a new Aspirin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.